Trial Profile

A Pilot Study Evaluating the Effect of NT-I7, a Long Acting Interleukin-7, to Enhance Immune Clearance of SARS-CoV-2

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Jul 2020 According to a NeoImmuneTech media release, the two trials will complement each other and speed up enrollment as well as increase the number of patients.
27 Jul 2020 According to a NeoImmuneTech media release, the company has received a study-may-proceed letter from the U.S. Food and Drug Administration (FDA) for this second study evaluating NT-I7 (efineptakin alfa), a long-acting human IL-7, for the treatment of COVID-19.This investigator-initiated Phase 1 trial is being conducted by Jian Li Campian, M.D., Ph.D. of Washington University School of Medicine, St. Louis.
11 May 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com